GlassScriptPhysician profile
Rosa M Neno
NPI 1407850894
$4,856.29
in general payments reported to CMS, 2019-2025
60 companies · $574 in 2025
The $574 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $481 · 2021: $819 · 2022: $709 · 2023: $807 · 2024: $626 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $612.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $397.53 | 2019-2025 | Mounjaro, Jardiance, Baqsimi |
| Pfizer INC. | $393.27 | 2019-2025 | |
| Abbvie INC. | $381.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $345.88 | 2020-2025 | Airsupra, Farxiga |
| Amgen INC. | $268.78 | 2019-2025 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $232.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.22 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Dexcom, INC. | $136.66 | 2022 | |
| Astellas Pharma US INC | $114.74 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $111.36 | 2019-2022 | |
| Exact Sciences Corporation | $109.14 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $108.94 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $88.19 | 2019-2024 | |
| Insulet Corporation | $84.14 | 2023-2025 | Omnipod |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Neno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.